Prevalence and incidence of dyslipidaemia among adults in Africa: A systematic review and meta-analysis protocol

BMJ Open

Volumn 5, Issue 3, 2015, Pages

  Noubiap, Jean Jacques N ^a,b   Nansseu, Jobert Richie N ^c   Bigna, Jean Joel R ^d   Jingi, Ahmadou M ^e   Kengne, André Pascal ^f  

^a Internal Medicine Unit Edea Regional Hospital   (Cameroon)

^b Serology Unit   (Cameroon)

^c Department of Paediatrics   (Cameroon)

^d Goulfey District Hospital   (Cameroon)

^e UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICA; BIBLIOGRAPHIC DATABASE; DATA SYNTHESIS; DYSLIPIDEMIA; HUMAN; INCIDENCE; META ANALYSIS; PREVALENCE; REVIEW; SYSTEMATIC REVIEW; DYSLIPIDEMIAS; METHODOLOGY;

ADULT; AFRICA; DYSLIPIDEMIAS; HUMANS; INCIDENCE; PREVALENCE; RESEARCH DESIGN;

EID: 84926512720     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-007404     Document Type: Review

References (24)

1. World Health Organization. Global status report on non communicable diseases 2010. Geneva, World Health Organization, 2011.
2. World Health Organization. Global atlas on cardiovascular disease prevention and control. Geneva, World Health Organization, 2011.
3. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2): S1-45.
4. Di Angelantonio E, Gao P, Pennells L, et al. Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-506.
5. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012;380:572-80.
6. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004;364:937-52.
7. World Health Organization. Global Health Observatory data. Cholesterol. http://www.who.int/gho/ncd/risk-factors/cholesterol-prevalence/en/ (accessed 14 Feb 2015).
8. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004;44:720-32.
9. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.
10. Baigent C, Blackwell L, Emberson J, et al., Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
11. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62.
12. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
13. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
14. Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934-9.
15. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296.
16. Barendregt JJ, Doi SA, Lee YY, et al. Meta-analysis of prevalence. J Epidemiol Community Health 2013;67:974-8.
17. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
18. Higgins IP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
19. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
21. Sumner AE, Zhou J, DOumatey A, et al. Low HDL-cholesterol with normal triglycerides levels is the most common lipid pattern in West Africans and Africans Americans with metabolic syndrome: implications for cardiovascular disease prevention. CVD Prev Control 2010;5:75-80.
22. Burgess PI, MacCormick IJ, Harding SP, et al. Epidemiology of diabetes retinopathy and maculopathy in Africa: a systematic review. Diabet Med 2013;30:399-412.
23. Stanifer JW, Jing B, TOlan S, et al. The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e174-81.
24. Connor MD, Walker R, Modi G, et al. Burden of stroke in black populations in sub-Saharan Africa. Lancet Neurol 2007;6:269-78.